105 related articles for article (PubMed ID: 8004569)
1. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract.
Sengeløv L; Kamby C; Schou G; von der Maase H
Cancer; 1994 Jul; 74(1):123-33. PubMed ID: 8004569
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
3. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years.
Sengeløv L; Kamby C; von der Maase H
Eur Urol; 2001 Jun; 39(6):634-42. PubMed ID: 11464051
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.
Bajorin DF; Dodd PM; Mazumdar M; Fazzari M; McCaffrey JA; Scher HI; Herr H; Higgins G; Boyle MG
J Clin Oncol; 1999 Oct; 17(10):3173-81. PubMed ID: 10506615
[TBL] [Abstract][Full Text] [Related]
5. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
[TBL] [Abstract][Full Text] [Related]
6. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan.
Abe T; Ishizaki J; Kikuchi H; Minami K; Matsumoto R; Harabayashi T; Sazawa A; Mochizuki T; Chiba S; Akino T; Murakumo M; Miyajima N; Tsuchiya K; Maruyama S; Murai S; Shinohara N
Urol Oncol; 2017 Feb; 35(2):38.e1-38.e8. PubMed ID: 27693091
[TBL] [Abstract][Full Text] [Related]
7. Prognostic model to predict survival in patients with metastatic upper tract urothelial carcinoma treated with cisplatin-based chemotherapy.
Hsieh MC; Su YL; Chiang PH; Rau KM; Chen YY; Huang CH
Int J Urol; 2016 May; 23(5):385-9. PubMed ID: 26992082
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of tumor necrosis in primary transitional cell carcinoma of upper urinary tract.
Lee SE; Hong SK; Han BK; Yu JH; Han JH; Jeong SJ; Byun SS; Park YH; Choe G
Jpn J Clin Oncol; 2007 Jan; 37(1):49-55. PubMed ID: 17204506
[TBL] [Abstract][Full Text] [Related]
9. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.
Vassilakopoulou M; de la Motte Rouge T; Colin P; Ouzzane A; Khayat D; Dimopoulos MA; Papadimitriou CA; Bamias A; Pignot G; Nouhaud FX; Hurel S; Guy L; Bigot P; Roumiguié M; Rouprêt M;
Cancer; 2011 Dec; 117(24):5500-8. PubMed ID: 21638278
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?
Matsuguma H; Yoshino I; Ito H; Goya T; Matsui Y; Nakajima J; Ikeda N; Okumura S; Shiono S; Nomori H;
Ann Thorac Surg; 2011 Aug; 92(2):449-53. PubMed ID: 21801905
[TBL] [Abstract][Full Text] [Related]
11. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.
Fosså SD; Sternberg C; Scher HI; Theodore CH; Mead B; Dearnaley D; Roberts JT; Skovlund E
Br J Cancer; 1996 Nov; 74(10):1655-9. PubMed ID: 8932351
[TBL] [Abstract][Full Text] [Related]
12. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
[TBL] [Abstract][Full Text] [Related]
15. Retroperitoneal lymph node dissection (RPLD) in conjunction with nephroureterectomy in the treatment of infiltrative transitional cell carcinoma (TCC) of the upper urinary tract: impact on survival.
Brausi MA; Gavioli M; De Luca G; Verrini G; Peracchia G; Simonini G; Viola M
Eur Urol; 2007 Nov; 52(5):1414-8. PubMed ID: 17507148
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma.
Takemura K; Fukushima H; Ito M; Kataoka M; Nakanishi Y; Sakamoto K; Suzuki H; Tobisu KI; Koga F
Urol Oncol; 2019 Feb; 37(2):108-115. PubMed ID: 30478012
[TBL] [Abstract][Full Text] [Related]
17. Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery.
Urakami S; Yuasa T; Yamamoto S; Sakura M; Tanaka H; Hayashi T; Uehara S; Inoue Y; Fujii Y; Masuda H; Fukui I; Yonese J
Int J Clin Oncol; 2015 Dec; 20(6):1171-8. PubMed ID: 25953680
[TBL] [Abstract][Full Text] [Related]
18. Salvage treatment with low-dose weekly paclitaxel in elderly or poor performance status patients with metastatic urothelial carcinoma.
Han JJ; Kim YJ; Kim JW; Chang H; Lee JO; Lee KW; Jeong CW; Kim JH; Hong SK; Bang SM; Byun SS; Lee SE; Lee JS
Tumori; 2014; 100(4):439-45. PubMed ID: 25296594
[TBL] [Abstract][Full Text] [Related]
19. Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
Giessen C; Stintzing S; Laubender RP; Ankerst DP; Schulz C; Moosmann N; Modest DP; Schalhorn A; von Weikersthal LF; Heinemann V
Clin Colorectal Cancer; 2011 Dec; 10(4):317-24. PubMed ID: 21729676
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
